Fish as Model Organism for the Identification of Marine Bioactive Compounds

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 3470

Special Issue Editor

Ctr Marine Sci CCMAR, Univ Algarve, 8005-139 Faro, Portugal
Interests: biomedicine; model organism; bone development; extracts from marine organisms; colorectal cancer; biomarker; vitamin
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear colleagues,                

Zebrafish (Danio rerio) and medaka (Oryzias latipes) are currently used as model organisms for the screening of molecules of interest for biomedical and pharmaceutical applications, and, in particular, for the identification of compounds capable of rescuing fish phenotypes mimicking human diseases. The marine environment, with its large diversity of habitats, hosts a plethora of species with a large diversity of physiological adaptations, which are the source of structurally unique natural products. In recent years, a number of molecules/extracts with specific biomedical applications have been isolated from marine organisms, and these proven to be effective in targeting prevalent and rare diseases or as sources to develop new analgesics, anti-inflammatory or antidiabetic drugs, to name only a few. The present Special Issue aims to bring together articles presenting a comprehensive overview of the use of fish as model organisms to identify marine derived compounds of biomedical interest.

Dr. M. Leonor Cancela
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine drugs
  • in vitro experiment
  • drug discovery
  • bioactive compounds
  • marine organisms

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 8778 KiB  
Article
Aerophobin-1 from the Marine Sponge Aplysina aerophoba Modulates Osteogenesis in Zebrafish Larvae
by Marta Carnovali, Maria Letizia Ciavatta, Ernesto Mollo, Vassilios Roussis, Giuseppe Banfi, Marianna Carbone and Massimo Mariotti
Mar. Drugs 2022, 20(2), 135; https://0-doi-org.brum.beds.ac.uk/10.3390/md20020135 - 11 Feb 2022
Cited by 5 | Viewed by 2498
Abstract
Longer life expectancy has led to an increase in efforts directed to the discovery of new healing agents for disorders related to aging, such as bone diseases. Harboring an incredible variety of bioactive metabolites, marine organisms are standing out as fruitful sources also [...] Read more.
Longer life expectancy has led to an increase in efforts directed to the discovery of new healing agents for disorders related to aging, such as bone diseases. Harboring an incredible variety of bioactive metabolites, marine organisms are standing out as fruitful sources also in this therapeutic field. On the other hand, the in vivo zebrafish model has proven to be an excellent low-cost screening platform for the fast identification of molecules able to regulate bone development. By using zebrafish larvae as a mineralization model, we have thus evaluated the effects of the crude acetonic extract from the marine sponge Aplysina aerophoba and its bromotyrosine components on bone development. Obtained results led to the selection of aerophobin-1 (1) as a promising candidate for applications in regenerative medicine, paving the way for the development of a novel therapeutic option in osteoporosis treatment. Full article
Show Figures

Graphical abstract

Back to TopTop